|Bid||11.20 x 800|
|Ask||12.50 x 1000|
|Day's Range||11.59 - 12.07|
|52 Week Range||9.18 - 19.00|
|Beta (5Y Monthly)||2.14|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -5.56% and 14.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Intellia (NTLA) is likely to provide an update on the IND application for its lead candidate NTLA-2001, currently being developed to address transthyretin amyloidosis.
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
The saga over who owns the valuable patents that cover CRISPR/Cas9 gene editing took a new turn this week with a court decision that goes against the Broad Institute of Harvard and MIT and two local startups.
Shares of CRISPR gene-editing companies tumbled Monday after the Chinese scientist who created the world's first genetically edited babies was sentenced to three years behind bars.
Two of the industry’s leading gene-editing experts have unveiled their next venture: a gene-silencing startup called Triplet Therapeutics.
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat […]
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
After signing two back-to-back deals with Novartis this year, small Boston-based startup IFM Therapeutics is ramping up its business development with a new incubator.
Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.
CRISPR Therapeutics and Vertex Pharmaceuticals released the first data from their early-stage trial testing the safety and effectiveness of a potential cure for the genetic blood disorders sickle cell disease and beta thalassemia.
The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.
Massachusetts is home to 36 of the 500 companies making this year’s ranking, with three local firms making the top 100 — including the No. 2 spot.
Axsome Therapeutics is on a tear this year - with shares skyrocketing over 3,000%. This comes as the biotech company's migraine drug posted successful results in a late-stage study. Yahoo Finance's Anjalee Khemlani joins Seana Smith on The Ticker to discuss.